Viatris Signs Licensing Deal with Lexicon Pharmaceuticals for Sotagliflozin
This licensing agreement leverages Viatris' expertise in cardiovascular diseases and its Global Healthcare Gateway, which offers partners ready access to more markets and patients worldwide through the company's unique global infrastructure and expertise.
Sotagliflozin | 18/10/2024 | By Aishwarya | 335
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy